hackint0sh/New-Dataset huggingface dataset:
By acquiring longitudinal patient-reported outcome before and after neurosurgical interventions, we aim to determine the regular postoperative course for specific surgical procedures, as well as any deviation thereof, depending on the occurrence and severity of AEs. We will evaluate the validity of existing AE classifications and, if necessary, propose a new patient-centered scheme. We hope that this will result in an increase in standardized reporting of patient outcome, and ultimately allow for evidence-based patient information and decision-making. conditions: Disc Disease conditions: Instabilities Lumbar conditions: Brain Tumor conditions: Aneurysm studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 400 type: ESTIMATED name: OP-Tracker App measure: Subjective Well-Being (SWI) measure: EQ-5D-5L measure: Rate of adverse events measure: Severity of adverse events measure: Correlation between TDN/CDG and SWI/QoL measure: Correlation between baseline factors and TDN grade measure: Difference between rate of adverse events and TDN distribution between different surgery groups sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kantonsspital St.Gallen status: RECRUITING city: St.Gallen zip: 9007 country: Switzerland name: Linda Bättig, MD role: CONTACT phone: +41 71 494 11 99 email: linda.baettig@kssg.ch lat: 47.42391 lon: 9.37477 hasResults: False
nctId: NCT06352697 id: DELI_MASLD briefTitle: Probiotic Lysate (Postbiotic and Metabiotic) Supplementation for Adults MASLD Patients (DELI_MASLD Study) overallStatus: COMPLETED date: 2023-02-01 date: 2023-12-31 date: 2023-12-31 date: 2024-04-08 date: 2024-04-09 name: Bogomolets National Medical University class: OTHER name: Taras Shevchenko National University of Kyiv name: Danylo Halytsky Lviv National Medical University name: Kyiv City Clinical Endocrinology Center name: Center for Innovative Medical Technologies of the National Academy of Sciences of Ukraine name: MirImmunoFarm name: Stellar Biotics briefSummary: The current study aim was to conduct placebo-controlled randomize clinical trial to assess the short-term efficacy and safety of postbiotics on hepatic fat content as measured by biochemichal hepatic steatosis indeces, serum lipid profile, transaminases activity and chronic systemic inflammatory markers in MASLD patients.
The study will include 3 periods. Screening period of up to 1 weeks to assess the eligibility to inclusion/exclusion criteria. Treatment period for 3 month where the participants will receive a twice daily oral dose of postbiotics (cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023) at the assigned dose of 100mg or placebo in capsules. During this period monthly phone contacts will be done for assessment of compliance and safety concerns. Follow-up period of up to 3 month. conditions: Metabolic Dysfunction Associated Steatotic Liver Disease conditions: Steatotic Liver Disease conditions: Hepatic Steatosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Randomization was done by the study statistician based on a computer-generated list. The groups were homogeneous according to age, sex and diagnostic criteria. The assignment of groups was blind to participants, research staff and outcome assessors moreover, to maintain blind parallel study the statistician was not aware of the allocation of participants to intervention whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 50 type: ACTUAL name: Probiotic lysate (postbiotic and metabiotc) name: Placebo measure: changes in fatty liver index (FLI) measure: hepatic steatosis index (HSI) measure: TyG index measure: Concentration of AST measure: Concentration of ALT measure: Concentration of Gamma-glutamyl Transferase (GGT) measure: Concentration of Total Cholesterol (TC) measure: Concentration of Tryglicerides (TG) measure: Concentration of LDL-Cholesterol (LDL-C) measure: Concentration of VLDL-Cholesterol (VLDL-C) measure: Concentration of HDL-Cholesterol (HDL-C) measure: Concentration of high sensitivity CRP (hs-CRP) measure: Concentration of IL-6 measure: waist circumferences (WC) measure: body mass index (BMI) measure: visceral fat content sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Bogomolets National Medical University city: Kyiv zip: 01601 country: Ukraine lat: 50.45466 lon: 30.5238 facility: Kyiv City Clinical Endocrinology Center city: Kyiv zip: 01601 country: Ukraine lat: 50.45466 lon: 30.5238 facility: Taras Shevchenko National University of Kyiv city: Kyiv zip: 01601 country: Ukraine lat: 50.45466 lon: 30.5238 facility: Center for Innovative Medical Technologies of the National Academy of Sciences of Ukraine city: Kyiv zip: 02000 country: Ukraine lat: 50.45466 lon: 30.5238 facility: Danylo Halytsky Lviv National Medical University city: Lviv zip: 79010 country: Ukraine lat: 49.83826 lon: 24.02324 hasResults: False
nctId: NCT06352684 id: DP0001-SEV-CAB-II id: RS-2023-00227526 type: OTHER_GRANT domain: Korea Ministry of Science and ICT briefTitle: Multi-Reader Multi-Case, Retrospective Study to Evaluate Effectiveness of CadAI-B for Breast overallStatus: ACTIVE_NOT_RECRUITING date: 2023-11-24 date: 2025-01-14 date: 2025-01-14 date: 2024-04-08 date: 2024-04-08 name: BeamWorks Inc. class: INDUSTRY name: Severance Hospital briefSummary: The purpose of this study is to evaluate the effectiveness of lesion detection and diagnosis-aiding software (CadAI-B for Breast) during ultrasound (US) examination conditions: Breast Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 1000 type: ACTUAL name: CadAI-B for Breast measure: Area Under the LROC Curve measure: Lesion detection sensitivity and specificity sex: FEMALE minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Yonsei University Severance Hospital city: Seoul zip: 03722 country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06352671 id: 023-286 briefTitle: Prospective Long-Term Outcomes of a Standardized Ross Procedure acronym: ROSS overallStatus: RECRUITING date: 2023-10-12 date: 2025-12-01 date: 2026-01-01 date: 2024-04-08 date: 2024-04-08 name: Baylor Research Institute class: OTHER briefSummary: This standardized prospective long-term outcome analysis will help reaffirm these findings via a multicenter patient cohort and describe the best practices/techniques for stabilization of the autograft and right ventricular outflow tract reconstruction. conditions: Ross Procedure (Pulmonary Autograft Replacement) studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 225 type: ESTIMATED measure: Survival of the patient at 1-, 5- and 10-year intervals measure: Rate of re-hospitalization measure: Rate of peri operative morbidity measure: Rate of re-operation measure: Rate of re-intervention measure: NYHA status measure: Anticoagulant usage measure: Bleeding events measure: Post operative infection sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Baylor Scott and White Heart Hospital status: RECRUITING city: Plano state: Texas zip: 75093 country: United States name: Rincy Rajan role: CONTACT phone: 469-814-4981 email: Rincy.Rajan@BSWHealth.org name: Sarah Hale role: CONTACT phone: 4698144845 email: sarah.hale@bswhealth.org name: William Brinkman, MD role: PRINCIPAL_INVESTIGATOR lat: 33.01984 lon: -96.69889 hasResults: False
nctId: NCT06352658 id: #1/2024 briefTitle: Efficacy of Mandibular Advancement Device for Mild-Moderate Apnea overallStatus: COMPLETED date: 2023-02-01 date: 2024-01-01 date: 2024-01-10 date: 2024-04-08 date: 2024-04-08 name: Nourhan M.Aly class: OTHER briefSummary: This was a prospective randomized controlled clinical trial that aimed to compare the efficacy of conventional and CAD CAM mandibular advancement device. conditions: Apnea studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 26 type: ACTUAL name: Conventional mandibular advancement device name: CAD CAM mandibular advancement device measure: Apnea hypopnea index measure: Epwoth sleeplness scale (ESS) measure: Oxygen saturation measure: Snoring index sex: ALL minimumAge: 30 Years maximumAge: 50 Years stdAges: ADULT facility: Faculty of Dentistry, Alexandria University, Egypt city: Alexandria country: Egypt lat: 31.21564 lon: 29.95527 hasResults: False
nctId: NCT06352645 id: STUDY00004879 briefTitle: Evaluation of Safety and Efficacy of Bixdo Ultra Compact Water Flosser overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-05-01 date: 2026-05-01 date: 2024-04-08 date: 2024-04-09 name: Tufts University class: OTHER name: Guangdong Bixdo Health Technology Co., Ltd. briefSummary: The objective of the present randomized controlled trial is to evaluate the safety and efficacy of the use of Bixdo A30 Pro Ultra Compact Water Flosser (also referred to as the "Bixdo A30 Portable Water Flosser Travel Set") in addition to a manual toothbrush on clinical parameters of inflammation and bacterial plaque removal. conditions: Plaque Induced Gingivitis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: randomized controlled clinical trial primaryPurpose: TREATMENT masking: NONE count: 165 type: ESTIMATED name: Bixdo Ultra Compact Water Flosser name: Manual toothbrush measure: Inflammation Reduction measure: Bacterial plaque removal sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tufts University School of Dental Medicine city: Boston state: Massachusetts zip: 02111 country: United States lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06352632 id: ACT-GLOBAL_Master briefTitle: A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke acronym: ACT-GLOBAL overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-04 date: 2034-04 date: 2024-04-08 date: 2024-04-23 name: The George Institute class: OTHER name: University of Calgary name: Berry Consultants briefSummary: Stroke is causing 6.6 million deaths and is a major cause of disability worldwide in 2019. There remains an urgent need for interventions that improve outcomes which can be implemented with wide applicability for stroke. ACT-GLOBAL is a multi-factorial, multi-arm, multi-stage, randomised, global adaptive platform trial for stroke, aiming to identify the treatment/s associated with the highest chance of improving outcome in stroke patients. In ACT-GLOBAL multiple questions will be evaluated simultaneously and sequentially as data accrues and can evaluate interactions between different treatment options. conditions: Stroke studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: FACTORIAL interventionModelDescription: Adaptive Platform Trial evaluating multiple interventions in multiple domains primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 20000 type: ESTIMATED name: Standard-dose intravenous tenecteplase name: Low-dose intravenous tenecteplase name: No intravenous tenecteplase name: Conservative Blood Pressure Control name: Moderate Blood Pressure Control name: Intensive Blood Pressure Control name: Placebo name: NoNO-42 measure: modified Rankin scale (mRS) scores measure: Excellent functional neurological outcome measure: Independent functional neurological outcome measure: Health Related Quality of Life measure: Mortality sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06352619 id: ACT-GLOBAL_AIS_03 briefTitle: Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within ACT-GLOBAL Adaptive Platform Trial acronym: ENCHANTED3/MT overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-04 date: 2026-04 date: 2024-04-08 date: 2024-04-23 name: The George Institute class: OTHER name: University of Calgary name: Changhai Hospital briefSummary: Several clinical trials have produced variable conclusions regarding the effects of intensive blood pressure (BP) lowering in post-EVT acute ischaemic stroke (AIS) patients. Although two trials indicate harm from very intensive target-based treatment (SBP \<130 mmHg), the others neutral effects in the SBP range 140-160 mmHg. The ENCHANTED3/MT domain of the ACT-GLOBAL platform trial aims to test different approaches to the treatment of elevated SBP in post-EVT AIS patients to find an optimal BP management strategy. ENCHANTED3/MT will randomize (1:1:1) up to 2,000 patients with SBP ≥150 mmHg post-EVT to conservative (no or minimal SBP reduction by 5-10mmHg or a target of 175-180mmHg if very-high baseline SBP \[≥180mmHg\]), moderate (SBP reduction by 10-20mmHg or a target of 160 ± 5, whichever is higher; no control if low-high baseline SBP \[150-160mmHg\]), or intensive (SBP reduction by 30-50mmHg or a target of 140±5 mmHg, whichever is higher) BP management. conditions: Ischemic Stroke, Acute studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 2000 type: ESTIMATED name: Conservative SBP Control name: Moderate SBP Control name: Intensive SBP Control measure: modified Rankin scale measure: Excellent functional neurological outcome measure: Independent functional neurological outcome measure: Health Related Quality of Life measure: Mortality measure: Ordinal shift of 7 levels of modified Rankin scale measure: National Institute of Health Stroke Scale (NIHSS) score measure: Any intracranial haemorrhage (ICH) measure: Symptomatic intracerebral haemorrhage (sICH) measure: Serious Adverse Event (SAE) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06352606 id: 36264PR558/2/24 briefTitle: Spinal and General Anesthesia in Neonates Undergoing Herniorrhaphy overallStatus: RECRUITING date: 2024-04-06 date: 2024-09-01 date: 2024-09-01 date: 2024-04-08 date: 2024-04-09 name: Tanta University class: OTHER briefSummary: The aim of this study is to compare spinal and general anesthesia in neonates undergoing herniorrhaphy. conditions: Spinal Anesthesia conditions: General Anesthesia conditions: Neonates conditions: Inguinal Herniorrhaphy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: NONE count: 74 type: ESTIMATED name: Spinal anesthesia name: General anesthesia measure: Heart rate measure: Heart rate measure: Mean arterial blood pressure measure: Incidence of bradycardia measure: Incidence of hypotension measure: Incidence of postoperative apnea measure: The duration of surgery measure: Need for postoperative O2 supplementation measure: Hospital stays sex: ALL minimumAge: 1 Day maximumAge: 1 Month stdAges: CHILD facility: Tanta University Hospitals status: RECRUITING city: Tanta state: ElGharbia zip: 31527 country: Egypt name: Mohammed S Elsharkawy, MD role: CONTACT phone: 00201148207870 email: mselsharkawy@med.tanta.edu.eg name: Ahmed E Abo ElKheir, MD role: PRINCIPAL_INVESTIGATOR lat: 30.78847 lon: 31.00192 hasResults: False
nctId: NCT06352593 id: 36264PR557/2/24 briefTitle: Intraoperative Dexmedetomidine Infusion in Endovascular Intervention for Aneurysmal Subarachnoid Hemorrhage overallStatus: RECRUITING date: 2024-04-06 date: 2024-09-01 date: 2024-09-01 date: 2024-04-08 date: 2024-04-09 name: Tanta University class: OTHER briefSummary: The aim of this study is to evaluate the role of intraoperative dexmedetomidine infusion in endovascular intervention for aneurysmal subarachnoid hemorrhage. conditions: Dexmedetomidine conditions: Infusion conditions: Endovascular conditions: Aneurysmal Subarachnoid Hemorrhage studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 90 type: ESTIMATED name: Intraoperative Dexmedetomidine name: Placebo measure: Incidence of vasospasm measure: Incidence of morbidity and mortality (M/M) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tanta University Hospitals status: RECRUITING city: Tanta state: ElGharbia zip: 31527 country: Egypt name: Mohammed S Elsharkawy, MD role: CONTACT phone: 00201148207870 email: mselsharkawy@med.tanta.edu.eg name: Ahmed E Abo ElKheir, MD role: PRINCIPAL_INVESTIGATOR lat: 30.78847 lon: 31.00192 hasResults: False
nctId: NCT06352580 id: COVID-19 Pediatric briefTitle: Covid-19 Pandemic and Pediatric Dentistry overallStatus: COMPLETED date: 2022-03-01 date: 2022-06-30 date: 2022-06-30 date: 2024-04-08 date: 2024-04-08 name: Abant Izzet Baysal University class: OTHER briefSummary: Coronavirus (SARS-CoV-2), which emerged in Wuhan, China in 2019 and causes severe respiratory infection, poses a potential risk for dentists and patients during dental treatments. It is a common situation during the pandemic period for parents of children needing dental treatment to want to postpone their children's treatment due to Covid-19. This study aimed to evaluate parents' concerns about their children's dentist appointments and ongoing dental treatments in the presence of the quarantine imposed due to Covid-19 and the Covid-19 vaccines that have started to be administered worldwide. In the study, an informative survey consisting of 26 questions was applied to determine how parents feel about the COVID-19 pandemic, how concerned they are about their children's oral health and dental treatment plan, and the changes caused by COVID-19 vaccination practices. The questions were created by 3 different experienced dentists and analysed by 2 different experienced dentists. Questions 7 and 26 were repeated at the beginning and end of the survey to give the same question and answer meaning. Thus, the reliability of the survey was tested. conditions: COVID-19 Pandemic studyType: OBSERVATIONAL observationalModel: FAMILY_BASED timePerspective: CROSS_SECTIONAL count: 438 type: ACTUAL name: Survey measure: Approach to dental treatments sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Deniz Sıla Özdemir Çelik city: Merkez state: Bolu zip: 14030 country: Turkey hasResults: False
nctId: NCT06352567 id: BakircayU1394/1414 briefTitle: Symptoms Associated With Chemotherapy-Induced Peripheral Neuropathy overallStatus: RECRUITING date: 2024-01-18 date: 2024-06-22 date: 2024-08 date: 2024-04-08 date: 2024-04-09 name: Izmir Bakircay University class: OTHER briefSummary: Breast cancer remains the most frequent type of cancer globally. Nevertheless, the increased rate of disease-free survival of breast cancer brought the specific need of managing of short and long-term side effects of multimodal treatment. Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most debilitating conditions which is characterized by a wide variety of experienceable symptoms by patients that need to be addressed in detail. Therefore, in this cross-sectional study, it was aimed to assess the potential symptoms associated with CIPN of patients with breast cancer who underwent systemic chemotherapy. In addition, it was aimed to assess the potential associations between experienced symptoms of CIPN and sociodemographic (age, body mass index etc.) and clinical features (mean exposed dose, type of surgery (if any) etc.). conditions: Chemotherapy-induced Peripheral Neuropathy conditions: Breast Cancer conditions: Breast Cancer Female studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 112 type: ESTIMATED name: European Organization for Research and Treatment of Cancer-Chemotherapy Induced Peripheral Neuropathy (EORTC-CIPN20) questionnaire measure: Assessment of perceived Chemotherapy Induced Peripheral Neuropathy symptoms sex: FEMALE minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Bakircay University Çiğli State and Training Hospital, Department of Medical Oncology status: RECRUITING city: İzmir state: Çiğli zip: 35620 country: Turkey name: Murat Akyol, MD role: CONTACT phone: +902324930000 email: dr-muratakyol@hotmail.com name: Alper Tuğral, PT, MSc role: CONTACT phone: +905074421420 email: alper.tugral@bakircay.edu.tr lat: 38.41273 lon: 27.13838 hasResults: False
nctId: NCT06352554 id: 2023/ETH02474:STING id: 224842/Z/21/Z type: OTHER_GRANT domain: Wellcome Trust id: 75A50122C00028 type: OTHER_GRANT domain: HHS/BARDA OTA briefTitle: Susceptibility Testing In Neisseria Gonorrhoeae (STING) Study, Assessing the Performance of a New Rapid Test for Gonorrhoea Antibiotic Resistance, in a Cohort of 100 Culture Positive Neisseria Gonorrhoeae Infections acronym: STING overallStatus: NOT_YET_RECRUITING date: 2024-04-08 date: 2024-12-30 date: 2025-01-30 date: 2024-04-08 date: 2024-04-09 name: SpeeDx Pty Ltd class: INDUSTRY name: Biomedical Advanced Research and Development Authority name: Wellcome Trust name: German Federal Ministry of Education and Research name: Australian Research Council Research Hub to Combat Antimicrobial Resistance briefSummary: This study aims to validate a novel antibiotic susceptibility test (InSignia) for gonorrhoea in patient clinical samples.
Furthermore, this study will also add to our understanding on the performance of this test in various clinical specimens. conditions: Diagnosis conditions: Gonorrhea conditions: Resistance Bacterial studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 100 type: ESTIMATED measure: To determine the feasibility of performing antibiotic susceptibility testing (AST) for Neisseria gonorrhoeae directly from patient samples using InSignia workflow and assay against commonly used & clinically relevant antibiotics. measure: To study the performance of the InSignia assay in determining antibiotic susceptibility of NG against commonly used & clinically relevant agents in clinical samples with comparison to gold standard methods. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06352541 id: SOPH232-1122/I briefTitle: Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo. acronym: PRO-232 overallStatus: NOT_YET_RECRUITING date: 2024-05-30 date: 2025-06-30 date: 2025-06-30 date: 2024-04-08 date: 2024-04-11 name: Laboratorios Sophia S.A de C.V. class: INDUSTRY briefSummary: This is a phase I study evaluating safety and tolerability through the incidence of unexpected adverse events and IOP measurement, as well as through the incidence of stinging after its administration, compared to placebo. conditions: Healthy studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Phase I, controlled, comparative, parallel groups, double blind, one center. primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Double blind. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 34 type: ESTIMATED name: PRO-232 name: Placebo measure: Incidence Unexpected Related Adverse Reactions measure: Changes in intraocular pressure (IOP) measure: Incidence of Stinging measure: Incidence of Expected Related Adverse Events measure: Changes in Best Corrected Visual Acuity (BCVA) measure: Changes in the integrity of the ocular surface (fluorescein staining) measure: Incidence of ocular symptoms (foreign body sensation and tearing) sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT hasResults: False